Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical Year-in-Review of Chronic Obstructive Pulmonary Disease in Korea

호흡기내과 의사를 위한 COPD 리뷰

  • Shin, Kyeong-Cheol (Department of Internal Medicine, Yeungnam University College of Medicine)
  • 신경철 (영남대학교 의과대학 내과학교실)
  • Received : 2011.05.28
  • Accepted : 2011.06.02
  • Published : 2011.07.30
Download PDF
⟨ Previous Next ⟩

Abstract

Many findings suggest that chronic obstructive pulmonary disease (COPD) imposes an enormous burden on patients, health-care professionals and society. COPD contributes to morbidity and mortality and to a significant use of health-care resources. In spite of a higher prevalence of COPD in Korea, the result of COPD treatment is not effective. The purpose of this article was to review recent advances in the study of COPD in Korea with the aim of improving effective management. This review highlights articles pertaining to the following topics; prevalence, assessment of COPD, risk factors for hospitalization, co-morbid diseases, phenotypes, and treatment issues.

Keywords

References

  1. Yoo KH, Kim YS, Sheen SS, Park JH, Hwang YI, Kim SH, et al. Prevalence of chronic obstructive pulmonary disease in Korea: the fourth Korean National Health and Nutrition Examination Survey, 2008. Respirology 2011;16:659-65. https://doi.org/10.1111/j.1440-1843.2011.01951.x
  2. Kim DS, Kim YS, Jung KS, Chang JH, Lim CM, Lee JH, et al. Prevalence of chronic obstructive pulmonary disease in Korea: a population-based spirometry survey. Am J Respir Crit Care Med 2005;172:842-7. https://doi.org/10.1164/rccm.200502-259OC
  3. Lee S, Lee JS, Song JW, Choi CM, Shim TS, Kim TB, et al. Validation of the Korean version of chronic obstructive pulmonary disease assessment test (CAT) and Dyspnea-12 questionnaire. Tuberc Respir Dis 2010;69:171-6. https://doi.org/10.4046/trd.2010.69.3.171
  4. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005-12. https://doi.org/10.1056/NEJMoa021322
  5. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD assessment test. Eur Respir J 2009;34:648-54. https://doi.org/10.1183/09031936.00102509
  6. Stoller JK, Ferranti R, Feinstein AR. Further specification and evaluation of a new clinical index for dyspnea. Am Rev Respir Dis 1986;134:1129-34.
  7. Yorke J, Moosavi SH, Shuldham C, Jones PW. Quantification of dyspnoea using descriptors: development and initial testing of the Dyspnoea-12. Thorax 2010;65:21-6. https://doi.org/10.1136/thx.2009.118521
  8. Kim MH, Lee K, Kim KU, Park HK, Jeon DS, Kim YS, et al. Risk factors associated with frequent hospital readmissions for exacerbation of COPD. Tuberc Respir Dis 2010;69:243-9. https://doi.org/10.4046/trd.2010.69.4.243
  9. Douglas SL, Daly BJ, Gordon N, Brennan PF. Survival and quality of life: short-term versus long-term ventilator patients. Crit Care Med 2002;30:2655-62. https://doi.org/10.1097/00003246-200212000-00008
  10. National Heart, Lung and Blood Institute; National Institutes of Health. Morbidity and mortality: 2007 chart book on cardiovascular, lung and blood diseases [internet]. Bethesda, MD: National Institutes of Health; 2007 [cited 2010 Oct 14]. Available from: http://www.nhlbi.nih.gov/resources/docs/07a-chtbk.pdf.
  11. Jeong SW, Lee JH, Choi KJ, Hwangbo Y, Kim YY, Lee YJ, et al. Comparisons of clinical characteristics and outcomes in COPD patients hospitalized with community-acquired pneumonia and acute exacerbation. Tuberc Respir Dis 2010;69:31-8. https://doi.org/10.4046/trd.2010.69.1.31
  12. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152:S77-121.
  13. Global Initiative for Chronic Obstructive Lung disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease [internet]. [place unknown]: GOLD; c2009. [cited 2009 Nov 18]. Available from: http//www.goldcopd.org.
  14. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204. https://doi.org/10.7326/0003-4819-106-2-196
  15. Kwon YS, Chi SY, Shin HJ, Kim EY, Yoon BK, Ban HJ, et al. Plasma C-reactive protein and endothelin-1 level in patients with chronic obstructive pulmonary disease and pulmonary hypertension. J Korean Med Sci 2010;25:1487-91. https://doi.org/10.3346/jkms.2010.25.10.1487
  16. Wright JL, Levy RD, Churg A. Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment. Thorax 2005;60:605-9. https://doi.org/10.1136/thx.2005.042994
  17. Jung HS, Lee JH, Chun EM, Moon JW, Chang JH. Predictors of long-term mortality after hospitalization for acute exacerbation of COPD. Tuberc Respir Dis 2006;60:205-14. https://doi.org/10.4046/trd.2006.60.2.205
  18. Barbera JA, Riverola A, Roca J, Ramirez J, Wagner PD, Ros D, et al. Pulmonary vascular abnormalities and ventilation-perfusion relationships in mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994;149:423-9. https://doi.org/10.1164/ajrccm.149.2.8306040
  19. Santos S, Peinado VI, Ramirez J, Melgosa T, Roca J, Rodriguez-Roisin R, et al. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J 2002;19:632-8. https://doi.org/10.1183/09031936.02.00245902
  20. Ballou SP, Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 1992;4:361-8. https://doi.org/10.1016/1043-4666(92)90079-7
  21. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993;82:513-20.
  22. Joppa P, Petrasova D, Stancak B, Tkacova R. Systemic inflammation in patients with COPD and pulmonary hypertension. Chest 2006;130:326-33. https://doi.org/10.1378/chest.130.2.326
  23. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-5. https://doi.org/10.1038/332411a0
  24. Allen SW, Chatfield BA, Koppenhafer SA, Schaffer MS, Wolfe RR, Abman SH. Circulating immunoreactive endothelin- 1 in children with pulmonary hypertension. Association with acute hypoxic pulmonary vasoreactivity. Am Rev Respir Dis 1993;148:519-22. https://doi.org/10.1164/ajrccm/148.2.519
  25. Ryu YJ, Chun EM, Lee JH, Chang JH. Prevalence of depression and anxiety in outpatients with chronic airway lung disease. Korean J Intern Med 2010;25:51-7. https://doi.org/10.3904/kjim.2010.25.1.51
  26. Crockett AJ, Cranston JM, Moss JR, Alpers JH. The impact of anxiety, depression and living alone in chronic obstructive pulmonary disease. Qual Life Res 2002;11:309-16. https://doi.org/10.1023/A:1015517606893
  27. Dahlen I, Janson C. Anxiety and depression are related to the outcome of emergency treatment in patients with obstructive pulmonary disease. Chest 2002;122:1633-7. https://doi.org/10.1378/chest.122.5.1633
  28. Jo KW, Ra SW, Chae EJ, Seo JB, Kim NK, Lee JH, et al. Three phenotypes of obstructive lung disease in the elderly. Int J Tuberc Lung Dis 2010;14:1481-8.
  29. Viegi G, Matteelli G, Angino A, Scognamiglio A, Baldacci S, Soriano JB, et al. The proportional Venn diagram of obstructive lung disease in the Italian general population. Chest 2004;126:1093-101. https://doi.org/10.1378/chest.126.4.1093
  30. Lee JS, Huh JW, Chae EJ, Seo JB, Ra SW, Lee JH, et al. Predictors of pulmonary function response to treatment with salmeterol/fluticasone in patients with chronic obstructive pulmonary disease. J Korean Med Sci 2011;26:379-85. https://doi.org/10.3346/jkms.2011.26.3.379
  31. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-303. https://doi.org/10.1136/bmj.320.7245.1297
  32. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-9. https://doi.org/10.1056/NEJM200012283432601
  33. Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:1084-91. https://doi.org/10.1164/rccm.2112055
  34. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89. https://doi.org/10.1056/NEJMoa063070
  35. BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD guidelines Group of the Standards of Care Committee of the BTS. Thorax 1997;52(Suppl 5):S1-28.
  36. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA. Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax 2003;58:654-8. https://doi.org/10.1136/thorax.58.8.654
  37. Lee JH, Lee YK, Kim EK, Kim TH, Huh JW, Kim WJ, et al. Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype. Respir Med 2010;104:542-9. https://doi.org/10.1016/j.rmed.2009.10.024
  38. Callahan CM, Dittus RS, Katz BP. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease: a meta-analysis. Ann Intern Med 1991;114:216-23. https://doi.org/10.7326/0003-4819-114-3-216